CN108884049A - 喹啉酮赖氨酰氧化酶样2抑制剂及其用途 - Google Patents

喹啉酮赖氨酰氧化酶样2抑制剂及其用途 Download PDF

Info

Publication number
CN108884049A
CN108884049A CN201780022652.7A CN201780022652A CN108884049A CN 108884049 A CN108884049 A CN 108884049A CN 201780022652 A CN201780022652 A CN 201780022652A CN 108884049 A CN108884049 A CN 108884049A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
aminomethyl
quinolin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780022652.7A
Other languages
English (en)
Chinese (zh)
Inventor
马丁·W·罗伯特姆
约翰·霍华德·哈钦森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmakea Inc
Original Assignee
Pharmakea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmakea Inc filed Critical Pharmakea Inc
Publication of CN108884049A publication Critical patent/CN108884049A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
CN201780022652.7A 2016-02-09 2017-02-07 喹啉酮赖氨酰氧化酶样2抑制剂及其用途 Pending CN108884049A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662293248P 2016-02-09 2016-02-09
US62/293,248 2016-02-09
PCT/US2017/016847 WO2017139274A1 (en) 2016-02-09 2017-02-07 Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN108884049A true CN108884049A (zh) 2018-11-23

Family

ID=59564012

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780022652.7A Pending CN108884049A (zh) 2016-02-09 2017-02-07 喹啉酮赖氨酰氧化酶样2抑制剂及其用途

Country Status (8)

Country Link
US (2) US10588900B2 (enExample)
EP (1) EP3414229B1 (enExample)
JP (1) JP2019508400A (enExample)
CN (1) CN108884049A (enExample)
AU (1) AU2017218889A1 (enExample)
CA (1) CA3013917A1 (enExample)
ES (1) ES2880766T3 (enExample)
WO (1) WO2017139274A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114286816A (zh) * 2019-07-25 2022-04-05 法玛西斯有限公司 赖氨酰氧化酶的二氟卤代烯丙胺砜衍生物抑制剂、其制备方法和用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6800872B2 (ja) * 2015-03-06 2020-12-16 ファーマケア，インク． リシルオキシダーゼ様２阻害剤とその使用
ES2880766T3 (es) 2016-02-09 2021-11-25 Pharmakea Inc Inhibidores de quinolinona lisil oxidasa similar al tipo 2 y usos de los mismos
EP3510404A4 (en) * 2016-09-07 2020-04-22 Pharmakea, Inc. CHEMICAL PROBES OF LYSYL-OXIDASE-LIKE 2 AND USES THEREOF
WO2019054386A1 (ja) * 2017-09-12 2019-03-21 学校法人工学院大学 複素環化合物又はその塩、ｇｐｒ３５作動薬及び医薬組成物
GB201716871D0 (en) 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds
US12233056B2 (en) 2022-04-06 2025-02-25 Syntara Limited Lysyl oxidase inhibitors for treating myeloid malignancies
JP2025525848A (ja) 2022-08-02 2025-08-07 ビーエーエスエフ ソシエタス・ヨーロピア ピラゾロ殺有害生物化合物
EP4467535A1 (en) 2023-05-25 2024-11-27 Basf Se Lactam pesticidal compounds
CN121219276A (zh) 2023-05-25 2025-12-26 巴斯夫欧洲公司 内酰胺杀有害生物化合物
WO2025256333A1 (en) 2024-06-13 2025-12-18 Syngenta Crop Protection Ag Pesticidally active aminoheterocycle derivatives

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0303387A1 (en) * 1987-08-12 1989-02-15 Merck Sharp & Dohme Ltd. Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders
US5021456A (en) * 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5118499A (en) * 1991-06-19 1992-06-02 Spyros Theodoropulos Quinoline polymers, their chelates and process of preparation and use
WO2002070515A2 (en) * 2001-01-26 2002-09-12 Pharmacia Italia Spa Chromane derivatives, process for their preparation and their use as antitumor agents
WO2006053555A2 (de) * 2004-11-22 2006-05-26 Elmar Reinhold Burchardt Pyrraz0l-3-on- und/oder pyridazin-3-onderivate als inhibitoren der lysyloxidase
WO2007105751A1 (ja) * 2006-03-16 2007-09-20 Astellas Pharma Inc. キノロン誘導体又はその製薬学的に許容される塩
WO2008115890A2 (en) * 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
CN101801933A (zh) * 2007-09-26 2010-08-11 安斯泰来制药株式会社 喹诺酮衍生物
CN102018698A (zh) * 2008-04-18 2011-04-20 盛诺基医药科技有限公司 治疗雌激素受体相关疾病的化合物及其方法
CN102239147A (zh) * 2008-12-05 2011-11-09 大塚制药株式会社 喹诺酮化合物及药物组合物
WO2012139045A1 (en) * 2011-04-08 2012-10-11 Gilead Biologics, Inc. Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
WO2012167237A2 (en) * 2011-06-03 2012-12-06 Medicines For Malaria Venture Compounds having antiparasitic or anti-infectious activity
WO2017015221A1 (en) * 2015-07-23 2017-01-26 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW274551B (enExample) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
IT1254469B (it) 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
EP0558245A1 (en) 1992-02-25 1993-09-01 RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors
US5474994A (en) 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
US5605896A (en) 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
EP0695753A1 (en) 1994-08-05 1996-02-07 Zeneca Limited Carbapenem derivatives containing a bicyclic substituent, process for their preparation, and their use
US5607928A (en) 1994-08-05 1997-03-04 Zeneca Limited Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives
AU4153496A (en) 1995-10-20 1997-05-07 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
GB0030729D0 (en) 2000-12-16 2001-01-31 Univ Nottingham Substituted-4-Quinolones
GB0116312D0 (en) 2001-07-04 2001-08-29 Univ Nottingham "Compositions containing N-acyl homoserine lactones"
WO2003088903A2 (en) 2002-04-17 2003-10-30 Cytokinetics, Inc. Compounds, compositions, and methods
US20050267120A1 (en) 2004-04-14 2005-12-01 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
JP2011231017A (ja) 2008-09-09 2011-11-17 Nissan Chem Ind Ltd 光学活性エポキシ化合物及び光学活性スルホキシド化合物の製造方法、並びに該方法に用いる配位子、錯体及び該錯体の製造方法
CA2740484C (en) 2008-10-17 2021-09-21 Akaal Pharma Pty Ltd S1p receptors modulators and their use thereof
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
AU2011240677B2 (en) 2010-04-12 2015-05-14 Somalogic Operating Co., Inc. 5-position modified pyrimidines and their use
EP2844647B1 (en) 2012-05-04 2020-07-22 Rhizen Pharmaceuticals S.A. Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
US9416139B2 (en) 2012-11-29 2016-08-16 Sunshine Lake Pharma Co., Ltd. Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
US9802949B2 (en) 2012-11-29 2017-10-31 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
CN103848820A (zh) 2012-11-29 2014-06-11 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
EP3041470A4 (en) 2013-09-04 2017-05-03 Board Of Regents Of the University Of Texas System Methods and compositions for selective and targeted cancer therapy
EP3330277A3 (en) 2013-11-21 2018-09-26 Somalogic, Inc. Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
JP2018522812A (ja) 2014-08-05 2018-08-16 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア カスパーゼ−６のモジュレーター
JP6800872B2 (ja) * 2015-03-06 2020-12-16 ファーマケア，インク． リシルオキシダーゼ様２阻害剤とその使用
EP3317258A4 (en) 2015-07-01 2019-06-26 Pharmakea, Inc. LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF
ES2880766T3 (es) 2016-02-09 2021-11-25 Pharmakea Inc Inhibidores de quinolinona lisil oxidasa similar al tipo 2 y usos de los mismos
WO2017197088A1 (en) 2016-05-12 2017-11-16 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors for the treatment of inflammatory conditions
BR112019004513A2 (pt) 2016-09-07 2019-06-18 Pharmakea Inc usos de um inibidor de lisil oxidase-like 2
EP3510404A4 (en) 2016-09-07 2020-04-22 Pharmakea, Inc. CHEMICAL PROBES OF LYSYL-OXIDASE-LIKE 2 AND USES THEREOF
WO2018048930A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
MA46204A (fr) 2016-09-07 2021-03-17 Pharmakea Inc Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabrication

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0303387A1 (en) * 1987-08-12 1989-02-15 Merck Sharp & Dohme Ltd. Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders
US5021456A (en) * 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5118499A (en) * 1991-06-19 1992-06-02 Spyros Theodoropulos Quinoline polymers, their chelates and process of preparation and use
WO2002070515A2 (en) * 2001-01-26 2002-09-12 Pharmacia Italia Spa Chromane derivatives, process for their preparation and their use as antitumor agents
US20040116497A1 (en) * 2001-01-26 2004-06-17 Gabriella Traquandi Chromane derivatives, process for their preparation and their use as antitumor agents
WO2006053555A2 (de) * 2004-11-22 2006-05-26 Elmar Reinhold Burchardt Pyrraz0l-3-on- und/oder pyridazin-3-onderivate als inhibitoren der lysyloxidase
WO2007105751A1 (ja) * 2006-03-16 2007-09-20 Astellas Pharma Inc. キノロン誘導体又はその製薬学的に許容される塩
CN101400655A (zh) * 2006-03-16 2009-04-01 安斯泰来制药有限公司 喹诺酮衍生物或其制药学可接受的盐
WO2008115890A2 (en) * 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
CN101801933A (zh) * 2007-09-26 2010-08-11 安斯泰来制药株式会社 喹诺酮衍生物
CN102018698A (zh) * 2008-04-18 2011-04-20 盛诺基医药科技有限公司 治疗雌激素受体相关疾病的化合物及其方法
CN102239147A (zh) * 2008-12-05 2011-11-09 大塚制药株式会社 喹诺酮化合物及药物组合物
WO2012139045A1 (en) * 2011-04-08 2012-10-11 Gilead Biologics, Inc. Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
WO2012167237A2 (en) * 2011-06-03 2012-12-06 Medicines For Malaria Venture Compounds having antiparasitic or anti-infectious activity
WO2017015221A1 (en) * 2015-07-23 2017-01-26 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
REGISTRY: "RN1500808-38-7", 《STN COLUMBUS》 *
REGISTRY: "RN1501920-10-0", 《STN COLUMBUS》 *
REGISTRY: "RN1538125-56-2", 《STN COLUMBUS》 *
STN: ""RN1521690-15-2，RN1522808-34-9，RN1529176-55-3，RN1533572-22-3，RN1521651-11-5"", 《REG》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114286816A (zh) * 2019-07-25 2022-04-05 法玛西斯有限公司 赖氨酰氧化酶的二氟卤代烯丙胺砜衍生物抑制剂、其制备方法和用途

Also Published As

Publication number Publication date
JP2019508400A (ja) 2019-03-28
CA3013917A1 (en) 2017-08-17
US11058676B2 (en) 2021-07-13
ES2880766T3 (es) 2021-11-25
EP3414229A1 (en) 2018-12-19
US10588900B2 (en) 2020-03-17
EP3414229A4 (en) 2019-10-16
AU2017218889A1 (en) 2018-08-30
EP3414229B1 (en) 2021-06-16
US20190046520A1 (en) 2019-02-14
US20200022972A1 (en) 2020-01-23
WO2017139274A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
US11058676B2 (en) Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
CN107592861B (zh) 氟化赖氨酰氧化酶样2抑制剂及其用途
CN107624110B (zh) 赖氨酰氧化酶样2抑制剂及其用途
CN113527293B (zh) Kras g12c突变蛋白抑制剂及其药物组合物、制备方法和用途
CN106220644B (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
JP2018521044A (ja) リシルオキシダーゼ様２阻害剤とその使用
JP2018519292A (ja) リシルオキシダーゼ様２阻害剤およびその使用
CN106573906A (zh) 哌啶‑二酮衍生物
CN105764903B (zh) 四环自分泌运动因子抑制剂
CN116744918A (zh) Hsd17b13抑制剂和其用途
WO2023066363A1 (zh) Parp-1降解剂及其用途
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
KR20230107802A (ko) Hsd17b13 억제제 및 이의 용도
JP3742593B2 (ja) ファルネシルトランスフェラーゼ阻害剤
CN117304182A (zh) 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用
HK1226074A1 (en) Tetracyclic autotaxin inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination